Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus DIPHENHYDRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus DIPHENHYDRAMINE HYDROCHLORIDE.
CLARITIN-D 24 HOUR vs DIPHENHYDRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine